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Chronic kidney disease (CKD) is an increasing and global health problem with a great economic burden for healthcare system.
Therefore to slow down the progression of this condition is a main objective in nephrology. It has been extensively reported
that microinflammation, immune system deregulation, and oxidative stress contribute to CKD progression. Additionally, dialysis
worsens this clinical condition because of the contact of blood with bioincompatible dialytic devices. Numerous studies have
shown the close link between immune system impairment and CKD but most have been performed using classical biomolecular
strategies. These methodologies are limited in their ability to discover new elements and enable measuring the simultaneous
influence of multiple factors. The “omics” techniques could overcome these gaps. For example, transcriptomics has revealed that
mitochondria and inflammasome have a role in pathogenesis of CKD and are pivotal elements in the cellular alterations leading to
systemic complications. We believe that a larger employment of this technique, together with other “omics” methodologies, could
help clinicians to obtain new pathogenetic insights, novel diagnostic biomarkers, and therapeutic targets. Finally, transcriptomics
could allow clinicians to personalize therapeutic strategies according to individual genetic background (nutrigenomic and
pharmacogenomic). In this review, we analyzed the available transcriptomic studies involving CKD patients.
1. Introduction
Chronic kidney disease (CKD) represents an increasing
global worldwide health problem particularly in elderly peo-
ple [1–3] and/or affected by diabetes, hypertension, and obe-
sity [4–6].Therefore, understanding the biologicalmachinery
associated with CKD represents an important objective in
nephrology and internal medicine.
During this condition, patients experience a gradual loss
of renal function over time with a progressive decline in the
glomerular filtration rate (GFR). An international consensus
categorized CKD into 5 stages according to the GFR [7]. In
the last stage of renal failure (called end stage renal disease,
ESRD) biochemical changes are incompatible with life and
renal replacement therapies (RRT: hemodialysis (HD) and
peritoneal dialysis (PD)) are necessary [8–11].
As the kidney is a complex and highly specialized organ,
with different functions (e.g., pH, plasma and tissue hydros-
aline balance, and vitaminD and erythropoietin production),
chronic kidney impairment may also determine signifi-
cant metabolic and endocrine changes (including acidosis,
hyperparathyroidism, and anemia) that may induce rele-
vant clinical complications (e.g., atherosclerosis, pericarditis,
osteodystrophy, and uremic encephalopathy) [12, 13].
Consequently, a healthy life style, with an adequate
physical activity and an equilibrate diet, with low salt intake
and no smoking habit, can undeniably prevent or slow down
the progression of renal damage and lessen complications
[14–17]. Treating diabetes and hypertension is alsomandatory
to control CKD and, as largely described, the introduction
of angiotensin-converting enzyme (ACE) inhibitors and
angiotensin receptor blockers (ARBs) is recommended to
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Figure 1: Schematic representation of the main factors involved in microinflammation and oxidative stress in chronic kidney disease (CKD).
As reported, (1) bioincompatible dialysis devices and plastificants; (2) classical inflammatory cytokines and new emerging biological elements
such as pentraxin-3 (PTX3), TNF-like weak inducer of apoptosis (TWEAK), and adipokines; (3) uremia-induced intestinal dysbiosis with an
increased translocation of gut bacteria and bacterial components into the circulation; and (4) mitochondrial deregulation may have a central
role in the onset of chronicmicroinflammatory state and oxidative stress and development ofmalnutrition, inflammation, and atherosclerosis
(MIA) syndrome, systemic complications, immune system deregulation, cardiovascular complications, and other systemic comorbidities in
CKD patients.
potentiate nephroprotection [18–23]. Low protein diets, then,
are required to reduce uremic symptoms until ESRD [24].
Additionally, the removal of the oxidative stress and
microinflammatory insults represents an additional powerful
therapeutic target in CKD [25, 26]. Unfortunately, in most
cases, this approach results in being ineffective and not
capable of stopping the progression of the kidney damage
toward renal failure. Moreover, during dialysis, the contact
of blood and/or tissues with bioincompatible devices may
dramatically worsen this pathological status [27–29].
2. Immune-Inflammatory
Deregulation in CKD
Several factors may be responsible of the chronic immune-
inflammatory state and oxidative stress in CKD patients (Fig-
ure 1) and classical inflammatory cytokines (tumor necrosis
factor-𝛼 (TNF-𝛼), interleukin- (IL-) 1, IL-6, and IL-10) [30–
32] and new emerging biological elements such as pentraxin-
3 (PTX3) [33, 34] and TNF-like weak inducer of apoptosis
(TWEAK) seem involved and significantly correlated to the
degree of the renal damage [35–37].
PTX3, a circulating acute phase protein with pattern
recognition molecule properties and with antibody-like
functions, contributes to innate immunity defence against
pathogens and in the regulation of inflammation inCKD [35–
37].
TWEAK can increase secretion of other cytokines locally
in the kidney and its blood levels seem independently
associated with coronary artery disease in patients with renal
damage [38, 39].
Adipokines, together with visfatin and leptin, were
found higher in CKD and in nondiabetic peritoneal dialysis
patients. Interestingly, leptin/adiponectin ratio was able to
predict mortality in a group of nondiabetic uremic patients
undergoing peritoneal dialysis treatment [40–42].
Interestingly, convincing recent evidences suggest that
uremia-induced intestinal dysbiosismay have a central role in
these processes by increasing the translocation of gut bacteria
and bacterial components into the circulation, which can in
turn activate systemic inflammation [43–45].
A recent cross-sectional study in stage 3-4 CKD demon-
strated that indoxyl sulfate and p-cresyl sulfate (nephro-
and cardiovascular toxins produced solely by the gut micro-
biota) were associated with elevated levels of inflammatory
biomarkers as well as with increased arterial stiffness [46].
Additionally, it has been largely reported that CKD
patients develop a complex immune dysfunction with an
interaction between the innate and adaptive systems, in
which immune activation (hypercytokinemia and acute
phase response) and immune suppression (impairment of
response to infections and poor development of adaptive
immunity) coexist [47]. Moreover renal replacement thera-
pies worsen the immune system deregulation.
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CKD progression and dialysis procedure contribute also
to protein-energy malnutrition, probably mediated by proin-
flammatory cytokines that can affect appetite and increased
protein hydrolysis and muscle protein breakdown [48].
The association between malnutrition, inflammation, and
atherosclerosis in this patient population has suggested the
existence of a syndrome called malnutrition, inflammation,
and atherosclerosis (MIA), which is associated with an
exceptionally high mortality rate [49].
To minimize these dialysis-related conditions [50, 51]
several pharmacological industries and researchers are work-
ing closely. However, at present, despite the great efforts, we
are still far from the standardization of a full biocompatible
dialysis procedure.
3. Oxidative Stress and Mitochondrial
Dysfunction in CKD
Oxidative stress andmitochondrial deregulation play amajor
role in CKD and, already from the early stage of CKD,
several markers of oxidative stress (e.g., malondialdehyde, F2
isoprostanes, and advanced oxidation protein products) are
plentiful with a concomitant decrease of antioxidants (e.g.,
superoxide dismutase, glutathione peroxidase, and vitamins
E and C) [26, 52–55].
The accumulation of uremic toxins, through the direct
augmentation of NADPH oxidase and xanthine oxidoreduc-
tase activities [56, 57], the inflammasome activation, and the
additional prooxidative stimuli due to the contact of PBMCs
with dialytic devices may induce a significant increment
of reactive oxygen species (ROS) [58, 59]. ROS are active
molecules able to oxidize proteins, lipids, and nucleic acids
with a subsequent damage of cells and tissues [26, 60].
Likewise, during PD conventional dialysis solutions, con-
taining high concentrations of glucose and glucose degra-
dation products, may increase ROS production in human
peritoneal mesothelial cells with consequent loss of ultrafil-
tration capacity, increased vascular density, and development
of fibrosis [61].
Oxidative stress is also accountable for the onset and
development of severe clinical complications (including car-
diovascular disease, atherosclerosis, hypertension, anemia,
and malnutrition) with a consequent low quality of life, high
risk of hospitalization, and short survival of CKD patients in
both conservative and dialysis treatment [28, 62–64].
Notably, recent studies have suggested that mitochondria
could be implicated in this CKD-associated prooxidative
machinery [9, 65].These organelles are involved in numerous
functions: ATP synthesis by oxidative phosphorylation, fatty
acids 𝛽-oxidation, synthesis of heme, apoptosis, synthesis of
steroid hormones, nitrogen balance through urea cycle, and
Ca homeostasis [66–68].
Structurally, they present an outer and inner membrane,
the latter of which would be impermeable to all molecules
in the absence of specific carriers and contains the OXPHOS
complexes. Electrons derived frommetabolic reducing equiv-
alents (NADH and FADH
2
) enter into the electron transport
chain through either complex I or complex II and via
respiratory chain to molecular oxygen which is finally
reduced to water.This exergonic process is used to pump pro-
tons from the mitochondrial matrix into the intermembrane
space, creating an electrochemical gradient used by complex
V for ATP synthesis [69].
During this process a small percentage (0.4–4%) of
electronsmay “leak” from the respiratory chain (in particular
at complexes I and III) and partially reduce oxygen, forming
superoxide anion (O
2
−) [70]. Consequentlymitochondria are
the major source of ROS in the cell.
Additionally, during CKD, patients’ cells undergo reduc-
tion in mitochondrial DNA (mtDNA) copy number, loss of
mitochondrial membrane potential (Δ𝜓m), and drop of ATP
production [71].
Mitochondria are also involved in apoptosis and epithelial
to mesenchymal transition of renal tubular epithelial cells
contributing to the fibrogenic process [72].
4. Transcriptomic Analysis Revealed an
Unrecognized and Specific Proinflammatory
and Prooxidative Biological/Cellular
Machinery in CKD
In the last two decades, researchers have tried to identify key
regulators of the intricate inflammatory pathway activated by
uremia “per se” and by dialysis, but, most of the time, this
research strategy based on single factor analysis is limited and
biased. Hence, a simultaneousmultifactorial analysis in CKD
appears more powerful and effective.
The recent development and extension of high-through-
put technologies have allowed reaching the above-mentioned
objective. In particular, microarray technology, which allows
the study of the entire transcriptome thanks to the hybridiza-
tion of nucleic acid (RNA) with dozens of thousands of
DNA probes attached to a solid support (such as glass,
plastic or silicon), has been revealed to be promising. Briefly,
transcripts extracted from samples are labeled with fluo-
rescent dyes and hybridize to their complementary targets.
Light intensity is then an indirect measurement of gene
expression. Transcriptome is the sum of RNA transcripts that
comprehend messenger RNAs, ribosomal and transfer RNA,
and regulatory noncoding RNAs [81–85].
This technology produces a large amount of raw data
that require specific statistical and bioinformatics tools in
order to avoid or minimize false positive and to obtain “more
conservative” results. In this context, a well conducted vali-
dation process by using standardized classical biomolecular
methodologies can reduce these biases.
As the other high-throughput (omics) sciences, no prior
hypothesis is made. Relationships among top selected genes
are, then, translated into biological pathway by using specific
software for functional analysis (e.g., Ingenuity Pathway
Analysis) [31, 86].
In the last ten years numerous studies have used this
approach in nephrology and the results have been very useful
in discovering new insights in the pathogenesis of CKD as
well as in the comorbidities associated with renal failure
(Table 1).
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Our group, in the 2008, has published one of the first
studies using this technology in dialysis [10]. Results of this
study clearly demonstrated, for the first time in dialysis,
that a group of genes (e.g., MIF, IL8RB, and CXCL12) has
a causative role in the microinflammatory/oxidative stress
in HD and PD patients and they were able to discriminate
dialysis from undialyzed CKD subjects (in pharmacological
conservative therapy). C-X-C motif chemokine 12 (CXCL12)
and IL-8 receptor, beta (IL8RB) were inversely correlated
to C-reactive protein (CRP) levels and highly expressed in
PD and CKD patients, respectively. Macrophage migration
inhibitory factor (MIF) was upregulated in HD patients and
directly correlated to CRP levels.
CXCL12 and its receptor, CXCR4, are important modu-
lators of inflammation and immune response. IL8RB binds
IL-8, a chemokine with proinflammatory and chemotactic
activity [87]. Previous reports have shown a decreased surface
expression of this receptor on PBMC of patients with severe
chronic inflammatory disease [88, 89].MIF encodes an “early
response” cytokine that plays an important pathogenic role
in numerous inflammatory disorders [90, 91]. It activates
macrophages to produce proinflammatory mediators and to
migrate to the sites of inflammation [92, 93]. In a mouse
model of spontaneous atherosclerosis, MIF blockade led to
a marked reduction of inflammation associated with the
disease [94].
These data were in line with those obtained by Friedrich
et al. [73] that, using a combined microarray and RT-
PCR approach, demonstrated thatHD treatment significantly
increased the transcript levels of several proinflammatory
cytokines, such as TNF-𝛼 and IL-8, C-C chemokine recep-
tor type 7 (CCR7), and the CX3C chemokine receptor 1
(CX3CR1). Dividing the patients into two groups, “high
CRP levels” and “low CRP levels,” they found that in the
latter the increment of transcript levels of anti-inflammatory
cytokine receptors (IL-1RN, IL-4R, IL-10R, and IFN𝛾-R1)
and chemokine receptors (CX3CR1, CXCR4, and CCR7) was
significantly more pronounced than in the high CRP group.
Similar results were obtained by Shah et al. [74] that
compared gene expression profile in muscle of healthy sub-
jects versus HD patients and its dynamic change in response
to HD. Genes in response to HD were a dynamic response
to activation of inflammation, apoptosis, and alterations in
cell cycle. In particular, GADD45B, a TNF𝛼-inducible gene
and a physiological target of nuclear factor-𝜅B (NF-𝜅B), was
upregulated [95].Theprotective activity ofGADD45B against
TNF-𝛼-induced programmed cell death involves suppression
of the c-Jun-N-terminal kinase cascade, a pathway usually
associated with cell death, and this suppression is central to
control of apoptosis by NF-𝜅B.
Transcriptomic profile was also influenced by different
dialysis procedures. Wilflingseder et al. clearly demonstrated
with microarray analysis conducted in PBMCs of four stable
HD patients that a large group of genes (𝑛: 172) were upreg-
ulated after treatment with semisynthetic membranes when
compared to full-syntheticmembranes [75].These geneswere
involved in immunity and defence, signal transduction, and
apoptosis. Dialysis with a full-synthetic membrane, on the
other hand, led to activation of 72 genes that were mainly
involved in cell cycle and cell cycle control.
Surprisingly, these results were different from those pub-
lished by Hochegger et al. [76] that did not find any sig-
nificant genetic difference between human polymorphonu-
clear neutrophils (PMN) stimulated with cuprophane versus
polysulfone. When these results were combined to one
group, the comparison with unstimulated cells revealed 50
genes differentially expressed with a marked upregulation of
FOS- and JUN-transcripts, but with only little activation of
immune response genes, and, contrarily to PMN stimulated
with E. Coli, no upregulation of apoptosis related transcripts.
Subsequently, our research group performed a research
project aimed at understanding the influence of dialysis
on the PBMCs’ immunotranscriptome [29]. As result, we
showed that patients with advanced renal impairment in
conservative pharmacological treatment (CKD stages III-IV)
exhibited a large amount of differentially expressed mRNAs
compared to those undergoing HD.
Among the genes downregulated in HD patients, we
identified those encoding the human leukocyte antigen-
(HLA-) G, a nonclassical major histocompatibility complex
class I molecule that differs from other HLA class I molecules
with regard to its low polymorphism, restricted tissue dis-
tribution, slow turnover, immunosuppressive properties, and
limited peptide diversity [96–98].
Under physiological conditions, the production of HLA-
G protein is restricted to trophoblast [99], thymic epithelial
cells [100], first-trimester placental chorionic blood ves-
sel endothelial cells [101], and IFN-𝛾-treated mononuclear
phagocytes [102]. However, the upregulation of this protein
can be detected in several pathological conditions such as
transplantation, tumors, viral infections, and autoimmune
diseases [103–107].
HLA-G possesses the capability to bind inhibitory recep-
tors such as the immunoglobulin-like transcripts 2 and 4
(ILT2, ILT4) and the killer immunoglobulin-like receptor
(KIR)2DL4/CD158d with inhibitory effects [107, 108].
HLA-G may also have a direct immune-inhibitory func-
tion through blocking effector cells and indirect immune-
inhibitory activity by regulatory cell generation. Via the
direct inhibitory functions, HLA-G is able to inhibit the
cytolytic activity and proliferation of NK [109], the antigen-
specific cytolytic functions of 𝛼/𝛽 and 𝛾/𝛿 T lymphocytes
[109, 110], the alloproliferative response of T cells [111, 112], the
proliferation of NK and T cells [113], and the DCsmaturation
[114].
Therefore, it is plausible that the lower HLA-G expression
in HD patients may determine a hyperactivation of T cells
and NK that could explain the different immune response of
dialyzed patients to viral infections and tumors.
Recently, Scherer et al. [77], in a study conducted in a
large subset of patients using Affymetrix Human Genome
U133 Plus 2.0 arrays, confirmed an important immune-
transcriptomic deregulation in CKD/ESRD patients and they
reported that several genes involved in complement pathway
and oxidativemetabolism and in response to stress and injury
were upregulated in uremia, while transcripts associated
with the clathrin-coated vesicle endosomal pathway were
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markedly reduced consistent with a defect in phagocytosis.
Key genes in the immune synapse and the T-cell receptor
signaling pathway were reduced, includingMHC-class II and
the T-cell receptor alpha/beta heterodimer, the coassociated
CD3 and CD4 molecules, and a variety of downstream
signaling components of the T-cell receptor pathway, the
CD28 receptor pathway, and the IL-2 response and signaling
pathway.
Moreover, Yokoi et al. [78] in a very well conducted and
elegant microarray study demonstrated an upregulation of
pleiotrophin in chlorhexidine gluconate (CG) induced peri-
toneal fibrosis mice versus controls.
This growth factor was found not only in fibroblasts
and mesothelial cells within the underlying submesothelial
compact zones of mice, but also in human peritoneal biopsy
samples and peritoneal dialysate effluent. In wild-type mice,
CG treatment increased peritoneal permeability, increased
mRNA level of TGF-𝛽1, TNF-𝛼, and IL-1𝛽, resulted in
infiltration of CD3-positive T cells, and caused a high number
of Ki-67-positive proliferating cells. Authors concluded that
the upregulation of pleiotrophin could play a central role in
local/systemic inflammation and fibrosis during peritoneal
injury.
Also genes involved in proteoglycans biosynthesis/meta-
bolism appear differentially expressed in dialyzed patients
[79] compared to healthy subjects (HS) or subjects with a low
degree of renal impairment (CKD/HS). Twenty-five genes
were upregulated (e.g., HPSE, VCAN, and VEGFA) and 45
downregulated (e.g., IDS and HEXA) in PD/HD compared
to CKD/HS. As well, gene expression and plasma activity
of heparanase (HPSE), one of the top selected upregulated
genes in PD/HD, were significantly correlated with the
inflammatory state measured by high-sensitive C reactive
protein (HS-CRP).
These results demonstrated that PBMCs of uremic
patients undergoing both peritoneal andhemodialysis exhibit
a chronic activation of the biosynthetic proteoglycans tran-
scriptomic pattern with heparanase being a central biological
element. This enzyme could be considered important for
rolling and leukocytes mobility in response of pathological
dialysis stimuli. In future, a pharmacological modulation of
HPSE could definitely mitigate these effects and reduce the
frequent CKD-associated vascular comorbidities.
Transcriptomic analysis demonstrated different expres-
sion of several genes involved in oxidative phosphorylation
system (OXPHOS) andmitochondrial function in ESRD/HD
patients compared to healthy subjects [9]. In particular, com-
plex IV activity, the terminal enzyme of the mitochondrial
respiratory chain that transfers the electrons from reduced
cytochrome c to oxygen [115], was significantly lower in
CKD/HD patients compared to healthy subjects demonstrat-
ing a reduced activity of OXPHOS in this population. This
is an important finding because it clearly demonstrated that
this organelle has a central role in the biological machinery
associated with renal failure.
Mitochondria aremajor source of cellularATPmolecules,
but if damaged, they may generate high levels of ROS
with massive clinical systemic consequences. Therefore,
modulating their function and biogenesis could turn to be a
valuable therapeutic option.
Finally, a combined research strategy between classi-
cal biomolecular strategies and high-throughput techniques
showed the Nod-like receptor protein 3 (NLRP3) inflam-
masome activation in dialyzed CKD patients [80]. NLRP3-
inflammasome is a cytoplasmic multiprotein complex of
three proteins: (1) NLRP3, (2) apoptosis-associated speck-like
protein containing CARD domain (ASC), and (3) caspase 1
(CASP-1). This complex is involved in the immune response
by activating two proinflammatory cytokines: IL-1𝛽 and IL-18
[116].
NLRP3 inflammasome can be activated by a lot of exoge-
nous and endogenous stimuli: pathogen-associated molecu-
lar patterns (PAMPs), such as bacterial and viral RNA [117–
119], and damage-associated molecular patterns (DAMPs)
such as urate crystals, calcium oxalate crystals, high glucose,
extracellular ATP, oxidized mitochondrial DNA, and ROS
[120].
The activation of NLRP3 inflammasome requires 2 spe-
cific signals. The first, or priming signal, converges on NF-
𝜅B to induce the transcription of inflammasome components,
IL-1𝛽 and IL-18, and the second signal leads to inflammasome
assembly [116].
ROS being able to activate the proinflammatory tran-
scription factors [121, 122] have a key role in the priming of
inflammasome activation [123].
The central role of mitochondrial ROS and NLRP3 acti-
vation has been reported also in the pathogenesis of albumin-
induced renal tubular injury [124–126].
5. Transcriptomics May Facilitate the
Development of a Personalized Medicine
for the Treatment of Microinflammation
and Oxidative Stress in CKD: Looking to
the Future
A correct analysis of transcriptomic/microarray results may
be useful to identify valuable biomarkers and to uncover
new therapeutic targets for CKD. This strategy could also
facilitate the employment of new available molecules/drugs
in nephrology (Figure 2).
Mainly, endogenous and food derived antioxidants, phy-
tochemicals, conventional drugs with favorable antioxidant
side effects, and mitochondria-targeted molecules seem
promising tools [9]. However, large randomized controlled
clinical trials are still lacking.
Among endogenous and food derived antioxidants L-
carnitine, coenzyme Q10 (CoQ10), alpha-lipoic acid (ALA),
omega 3 polyunsaturated fatty acids (Omega-3 PUFAs), and
vitamins E and vitamin C have demonstrated direct and
indirect antioxidant actions in clinical studies conducted in
CKD and HD patients [9].
Several phytochemicals such as thymoquinone (from
Nigella sativa or black cumin), curcumin, quercetin, resvera-
trol, and green tea polyphenols are promising substances that
could improve CKD outcome, acting against oxidative stress
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Figure 2: Site of action of most common endogenous and food derived antioxidants, phytochemicals, and conventional drugs with favorable
antioxidant side effects and new availablemore selective anti-inflammatorymedications. Some food derived antioxidants and drug (captopril)
have both direct antioxidant effect acting as a scavenger of free radicals or inhibiting lipid peroxidation and indirect effect by modulating the
activity of transcription factors NF-𝜅B and Nrf2. NF-𝜅B regulate the expression of proinflammatory genes (cytokines and chemokines) while
Nrf2 mediates the synthesis of antioxidant enzymes such as SOD, CAT, and GPx. Carvedilol prevents mitochondrial dysfunction induced
by oxidative stress and has protective effects against lipid peroxidation. GSH is a potent antioxidant depleted during oxidative stress and its
level can be modulated by omega 3, carvedilol, L-carnitine, and alpha-lipoic acid. MitoQ, MitoSOD, mitoE, mt-CPPs, and SS-peptides are
mitochondria-targeted molecules able to shuttle antioxidants into the mitochondria more efficiently than antioxidants molecules alone, in
order to reduce ROS production.
and preventing mitochondrial damage, as showed in numer-
ous animal models. Clinical data are already available for
curcumin supplementation in type-2 diabetic nephropathy,
lupus nephritis, and CKD; it was able to reduce proteinuria
and to prevent myocardial remodeling [9].
Also conventional and routinely used drugs may have
favorable antioxidant side effects. For example, captopril has
a thiol group in its structure that scavenges ROS and increases
antioxidants enzyme levels.
Unfortunately, most of these molecules are unable to
reach mitochondria at therapeutic dosage. For this reason
“shuttle” molecules to better deliver antioxidants into the
mitochondria are a growing field of interest.
First synthesized mitochondria target molecule was
MitoE that is vitamin E conjugatedwith a lipophilicmolecule,
triphenylphosphonium (TPP). Then, with the same tech-
nique, MitoQ (a quinone linked to TPP), MitoSOD (a
mimetic of MnSOD linked to TPP), and Mito-TEMPO (a
nitroxide linked to TPP) were also produced. Phase I and II
clinical trials are ongoing for MitoQ [9].
More recently even more efficacious peptides have been
introduced: Szeto-Schiller peptides (SS) and mitochondrial
cell-penetrating peptides (mt-CPPs) [127–129]. Two clin-
ical trials are ongoing to test SS-31 efficacy to prevent
ischemic-reperfusion injury in acute coronary events and
to prevent renal function loss after renal artery angioplasty
(NCT01755858).
Moreover, pharmaceutical companies are initiating new
research programs to discover and develop potent, selective
anti-inflammatory medications. Among them, bardoxolone
methyl (activators of Nrf2) has been the first to reach
full clinical development. It induces the antioxidant and
cytoprotective transcription factor Nrf2, reduces the proin-
flammatory activity of the IKK-𝛽/NF-𝜅B pathway, increases
the production of antioxidant and reductive molecules, and
decreases oxidative stress [130].
Another interesting compound is the primary amine
of ethanolamine [131] (PEA), a naturally occurring N-
acylethanolamine (NAE) that has protective effects in several
animal models [132]. PEA acts locally penetrating the cells
by passive transfer, due to its high lipophilicity, and by cells
through a facilitated transport system [133].
PEA was first discovered in the late 1950s by studying
the antiallergic and anti-inflammatory activity exerted by
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dietary supplementationwith egg yolk, peanut oil, or soybean
lecithin [134] due to a specific lipid fraction corresponding to
PEA [135].
Anti-inflammatory and protective activities of PEA were
confirmed in several models of inflammation, that is,
carrageenan-induced paw edema, adjuvant-induced arthritis,
tuberculin hypersensitivity, and ischemia reperfusion injury
[131, 136, 137].
Finally, also peroxisome proliferator-activated receptors
(PPARs), nuclear hormone receptors that stimulate tran-
scription of genes by binding to specific DNA sequences,
have demonstrated beneficial effects on vascular function
[138]. In particular, PPAR-𝛼, which is highly expressed in
kidney, liver, and heart, has been shown to be involved in the
control of blood pressure and consequently cardiovascular
complications [139, 140].
Moreover PPAR-𝛼 agonists (fenofibrates) exert renopro-
tective effect through anti-inflammatory [141] and antiox-
idant properties via the downregulation of inflammatory
cytokines and reduction of oxidative stress [142].
Moreover, the renoprotective effect of exogenous PPAR-
𝛼 agonists (WY 14643 and ciprofibrate) through a regulation
of megalin has been demonstrated in porcine epithelial cell
line derived from kidney proximal tubule (LLC-PKI) and in
BALB/c mice made albuminuric by bovine serum albumin
(BSA) administration [143].
Therefore, to obtain the best results with these drugs
it could be important to personalize administration and to
properly identify the “right patient for the right medication.”
Transcriptomic strategy could help to reach this objective.
6. Conclusion
Transcriptomic analysis, although still not largely employed
in nephrology, has demonstrated great speculative potential-
ities. Several key regulators of the immune-inflammatory and
oxidative stress pathways in CKD have been identified by
using this innovative technology.
Additionally, it has demonstrated a unique capability
to help clinicians to personalize patients’ treatment accord-
ing to their multigenetic expression fingerprint. A “cus-
tomized” drug and diet administration (nutrigenomic and
pharmacogenomic), by permitting the introduction of inno-
vative therapeutic protocols including new antioxidant and
anti-inflammatory compounds (e.g., endogenous and food
derived antioxidants, phytochemicals, and mitochondria-
targeted molecules), could definitely have a remarkable clin-
ical and therapeutic impact.
Recently, M. R. Shahidi Bonjar and L. Shahidi Bonjar
[144] have proposed and published an ideal and hypothetical
device that, in future, could be used to improve homeostasis
in patients with CKD. The device contains a quantitative
microarray detector (QMD) which measures the concen-
trations of uremic waste and toxins of interest. These data
are transmitted continuously to the homeostasis-oriented
microarray column (HOMC) in order to communicate how
much of each compound to retain. The patient’s blood would
flow through the tubing and proposed device to get close to
constituents of the normal blood plasma near to homeostatic
proportion. The device would be preprogrammed to remove
set amounts of uremic waste and toxins from the blood, and
the settings would be manually adjusted under the direction
of a nephrologist according to the needs of the individual
patient. When removal is sufficient, the QMD electronically
detects the adequacy of hemodialysis or a near homeostasis
condition and signals the end of treatment on the machine
monitor.
However, to enforce the routine use of this methodology,
researchers should work more to make data analysis and
interpretation easily accessible to medical doctor not expert
in statistics and bioinformatics and to reduce cost-consuming
of microarray experiments.
For these reasons, at the moment, we are still far from
large employment of this methodology in the nephrology
research and in daily clinical practice. To achieve this objec-
tive a multidisciplinary network (including medical doctors,
biologists, and statisticians) should be developed.
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